SillaJen Inc Asset Resilience Ratio

Latest as of September 2025: 50.41%

SillaJen Inc asset resilience ratio. SillaJen Inc (215600) has an Asset Resilience Ratio of 50.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 215600 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩62.70 Billion
≈ $42.49 Million USD Cash + Short-term Investments

Total Assets

₩124.38 Billion
≈ $84.29 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of SillaJen Inc (2016–2024)

Asset resilience ratio of SillaJen Inc from 2016 to 2024. This chart shows how SillaJen Inc's Asset Resilience Ratio has changed over time. Read total liabilities of SillaJen Inc for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down SillaJen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SillaJen Inc balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩62.70 Billion 50.41%
Total Liquid Assets ₩62.70 Billion 50.41%

Asset Resilience Insights

  • Very High Liquidity: SillaJen Inc maintains exceptional liquid asset reserves at 50.41% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

SillaJen Inc Industry Peers by Asset Resilience Ratio

Compare SillaJen Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

SillaJen Inc Asset Resilience Ratio by Year (2016–2024)

SillaJen Inc asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for SillaJen Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 78.85% ₩117.51 Billion
≈ $79.63 Million
₩149.02 Billion
≈ $100.99 Million
+14.59pp
2023-12-31 64.26% ₩49.30 Billion
≈ $33.41 Million
₩76.71 Billion
≈ $51.99 Million
+3.88pp
2022-12-31 60.38% ₩62.46 Billion
≈ $42.33 Million
₩103.45 Billion
≈ $70.10 Million
-19.92pp
2021-12-31 80.30% ₩108.26 Billion
≈ $73.37 Million
₩134.83 Billion
≈ $91.37 Million
+36.77pp
2020-12-31 43.53% ₩20.64 Billion
≈ $13.99 Million
₩47.42 Billion
≈ $32.14 Million
+38.36pp
2018-12-31 5.18% ₩10.00 Billion
≈ $6.78 Million
₩193.19 Billion
≈ $130.92 Million
-9.29pp
2017-12-31 14.47% ₩34.00 Billion
≈ $23.04 Million
₩234.95 Billion
≈ $159.23 Million
-39.33pp
2016-12-31 53.80% ₩152.85 Billion
≈ $103.59 Million
₩284.13 Billion
≈ $192.55 Million
--
pp = percentage points

About SillaJen Inc

KQ:215600 Korea Biotechnology
Market Cap
$188.15 Million
₩277.64 Billion KRW
Market Cap Rank
#16578 Global
#616 in Korea
Share Price
₩2010.00
Change (1 day)
+1.82%
52-Week Range
₩1844.00 - ₩4975.00
All Time High
₩121250.15
About

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more